Drug intelligence / Profile preview

gosogliptin

Development stage: Phase 3
Lead developer: SatRx
Modality: Small Molecules
Administration: Oral

Overview

Gosogliptin is a potent, selective, and orally bioavailable small molecule inhibitor of dipeptidyl peptidase 4 (DPP-4), also known as CD26. It belongs to the class of antihyperglycemic agents called gliptins. By inhibiting DPP-4, gosogliptin prevents the degradation of incretin hormones such as GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing their activity and improving glycemic control in patients with type 2 diabetes mellitus. Gosogliptin was originally discovered and developed by Pfizer through early clinical phases and later further developed by SatRx. It is approved for use in Russia for the treatment of type 2 diabetes mellitus[1][3][7].

Brand names: Saterex
Other names: gosogliptin869490-23-3869490-47-1

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on gosogliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gosogliptin.

Explore the full profile